Moderna, Inc. (MRNA) shares experienced a significant intraday decline of 5.05% on Friday. The sharp drop followed news of a major leadership change at the biotechnology company.

The movement was triggered by the announcement that Chief Medical Officer Dr. Jacqueline Miller will step down from her role effective March 2. Miller, who joined Moderna in 2020, led the development of the company's mRNA-based COVID-19 vaccine Spikevax and has been instrumental in multiple vaccine approvals. Her departure comes at a critical time as Moderna seeks to address declining revenue from COVID products and expand its mRNA platform into a broader franchise.

Moderna has named David Berman, formerly of Immunocore, as Chief Development Officer beginning March 2. Miller will remain as a consultant to assist with the transition. The executive change appears to have shaken investor confidence, contributing to the stock's downward pressure during the trading session.